ClinicalTrials.Veeva

Menu

Efficacy and Safety of Nokyong Mixture Extract(CME-PI) on Promotion of Immunity

C

Chonbuk National University

Status

Completed

Conditions

Immunity

Treatments

Dietary Supplement: Nokyong Mixture Extract(CME-PI)
Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04010331
DC-PI-CME

Details and patient eligibility

About

This study was conducted to investigate the efficacy and Safety of Nokyong Mixture Extract(CME-PI) on Promotion of Immunity

Full description

This study was a 8 weeks, randomized, double-blind, placebo-controlled human trial. 80 subjects were randomly divided into Nokyong Mixture Extract(CME-PI) group or placebo group. The investigators measured Natural Killer cell activity, Cytokines(IL-2, IL-12, IFN-γ, TNF-α), questionnaire scores of upper airway infection.

Enrollment

80 patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adult men and women over 50 years
  • After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice

Exclusion criteria

  • If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕

  • Those who received influenza vaccination within 3 months before the screening

  • Those who have a body mass index(BMI) of less than 18.5 kg / m^2 or greater than 35 kg / m^2 at the screening

  • Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic

  • Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening

  • Those who have received antipsychotic medication within 3 months before screening

  • Those who alcoholic or drug abuse suspected

  • Those who participated in other clinical trials within 3 months before screening

  • Laboratory test by show the following results

    • Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit
    • Serum Creatinine > 2.0 mg/dL
  • Pregnancy or breast feeding

  • Those who doesn't accept the implementation of appropriate contraception of a childbearing woman

  • Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups, including a placebo group

Nokyong Mixture Extract(CME-PI) group
Experimental group
Description:
2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 1 g/day)
Treatment:
Dietary Supplement: Nokyong Mixture Extract(CME-PI)
Placebo group
Placebo Comparator group
Description:
2 times a day, 2 capsule for 1 time, after breakfast/dinner meal(1.4g/day, Nokyong Mixture Extract(CME-PI) 0 g/day)
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems